Nitrosylcobalamin Selectively Targets Tumors via Cobalamin Uptake and Lysosomal Processing
Frontiers in Bioscience-Elite · 2026-03-10 · 18 (1)
DOI: 10.31083/fbe42272 ↗At a glance
Journal article in Frontiers in Bioscience-Elite, published online on 2026-03-10. Written by Joseph A Bauer and 1 co-authors. Institution: Nitric Oxide Services, LLC, Akron, OH 44312, USA. Major MEDLINE topics: Vitamin B 12, Lysosomes, Nitroso Compounds, Neoplasms. 43 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Nitrosylcobalamin (NO-Cbl) is a vitamin B12 analog designed to exploit the “Trojan horse” vulnerability created by the heightened need of cancer cells for cobalamin and one-carbon metabolism. Building on our recent biophysical studies confirming the affinity of NO-Cbl for intrinsic factor, this work aimed to investigate the mechanistic basis for the selective anticancer activity of NO-Cbl through the cobalamin transport axis and lysosomal processing. Materials and Methods: Human cancer cell lines (NIH-OVCAR-3, MCF-7, WM9, and DU145) were cultured and transfected to overexpress transcobalamin II (TCII). Cell proliferation and cytotoxicity were measured using the sulforhodamine B (SRB) assay. TCII-R (CD320) expression was quantified by flow cytometry. The impact of anti-CD320 antiserum and lysosomal alkalization (chloroquine) on NO-Cbl activity was assessed.
Results
Antiserum inhibition of the TCII receptor resulted in dose-dependent inhibition of NIH-OVCAR-3 and MCF-7 cell proliferation. Lysosomal alkalinization by chloroquine pretreatment abrogated NO-Cbl-induced cytotoxicity in OVCAR-3 cells. Flow cytometric analysis demonstrated an inverse correlation between TCII-R (CD320) expression (MFI ratio) and NO-Cbl ID50. TCII overexpression significantly reduced NO-Cbl ID50 in NIH-OVCAR-3 cells.
Conclusion
NO-Cbl utilizes tumor cell cobalamin transport and processing pathways to deliver nitric oxide selectively to cancer cells. These results, integrated with recent binding studies, validate NO-Cbl as a cobalamin-based targeted anticancer agent with efficacy in tumors expressing high levels of TCII and CD320.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Nitric Oxide Services, LLC, Akron, OH 44312, USA.
- Bauer Research Foundation, Inc., Akron, OH 44312, USA.
Cite
APA
Bauer, J. A., & Sysel, A. M. (2026). Nitrosylcobalamin Selectively Targets Tumors via Cobalamin Uptake and Lysosomal Processing. Frontiers in Bioscience-Elite, 18(1). https://doi.org/10.31083/fbe42272
Vancouver
Bauer JA, Sysel AM. Nitrosylcobalamin Selectively Targets Tumors via Cobalamin Uptake and Lysosomal Processing. Frontiers in Bioscience-Elite. 2026;18(1). doi:10.31083/fbe42272
BibTeX
@article{Bauer2026,
author = {Bauer, Joseph A and Sysel, Annette M},
title = {Nitrosylcobalamin Selectively Targets Tumors via Cobalamin Uptake and Lysosomal Processing},
journal = {Frontiers in Bioscience-Elite},
year = {2026},
volume = {18},
number = {1},
doi = {10.31083/fbe42272}
}
EUVIMED